KPC Pharmaceuticals, Inc. announcement: The fourth extraordinary shareholder meeting passed the proposal of acquiring 51% equity transfer of Kunming CR Sanjiu Pharmaceutical Co. Ltd. as well as the relevant trade with China Resources Sanjiu Medical & Pharmaceutical Co. Ltd., with a total investment of RMB 1.791 billion raised by self or internal funds. The company intends to sign an equity transfer agreement with its affiliate China Resources Sanjiu Medical & Pharmaceutical Co. Ltd. to acquire 51% of Kunming CR Sanjiu Pharmaceutical Co. Ltd.'s shares held by China Resources Sanjiu Medical & Pharmaceutical Co. Ltd.
昆药集团：通过收购昆明华润圣火药业51%股权的议案
KPC Pharmaceuticals, Inc.: Proposal to acquire 51% equity of Kunming CR Shenghuo Pharmaceutical Co., Ltd. has been approved.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.